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Abstract 
Hepatocyte nuclear factor 4 alpha (HNF4A) also 
known as NR2A1 (Nuclear Receptor Subfamily 2, 
group A, member 1) is a member of the nuclear 
receptor (NR) superfamily of ligand-dependent 
transcription factors. The encoded protein controls 
the expression of several genes, especially those that 
play distinct roles in development,  
differentiation, embryogenesis and organogenesis. 
Keywords: HNF4A 
Identity 
HGNC (Hugo): HNF4A 
Location 
The human HNF4A gene is located on 20q12-q13.1 
Figure 1 HNF4A transcripts.  HNF4A contains two distinct promoters (P1 and P2) that drive expression of 9 known isoforms 
(α1 to α9) of the gene. Transcription through the P1 promoter allows transcription starting from exon 1 (B) coding for the N-
terminal domain of HNF4A, designated as AF-1. Transcription through the P2 promoter allows the inclusion of exon 1 (A) but the 
exclusion of the exon 1 (B). Although alternative splicing of exon 1 (B) modifies only A/B domain of the P1 isoforms, F domains 
of both isoforms are modified by alternative splicing of the last exons. DBD: DNA binding domain; LBD: Ligand binding domain; 
AF-1: Activating function-1; AF-2: Activating function-2 (Modified from Babeu and Boudreau, 2014). 
HNF4A (Hepatocyte Nuclear Factor 4 alpha) Tunçer S, Banerjee S 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(2) 45 
 
 
Figure 2 HNF4A domains.  AF-1: activation function; DBD: DNA binding function; LBD: ligand binding function; F domain: 
repressor function that inhibits access of coactivators to NCOA5 (AF-2) which function in homodimerization and activation. H: 
hinge region. 
 
DNA/RNA 
Description 
The human HNF4A gene spans ~77 kb. 
Transcription 
The HNF4A gene is composed of thirteen exons and 
contains two promoters, P1 and P2, which can drive 
the expression of many splice variants (HNF4A1-
HNF4A9) that differ in the variable A/B and F 
domains (Harries et al., 2008). The variants derived 
from the P1 and P2 promoters are referred to as 
HNF4A1-HNF4A6 and HNF4A7-HNF4A9, 
respectively (Erdmann et al., 2007). 
The different promoters are used in different tissues 
and at different times during development, and the 
encoded protein controls the expression of several 
genes. Multiple isoforms are proposed to exist in 
mammals and are thought to have different 
physiological roles in development and 
differentiation (Walesky and Apte, 2015). 
Protein 
Description 
Domain structure and DNA binding 
HNF4A consists of six structural domains named A-
F that are responsible for specific functions: an N-
terminal activation domain (AF-1, also referred to as 
A/B domain); a zinc finger domain that serves as the 
DNA-binding domain (DBD; C domain) which is 
highly conserved among NRs; a putative ligand 
binding domain (LBD; E domain); and a C-terminal 
domain which functions in homodimerization and 
activation (AF-2), and a repressor region (F domain) 
that inhibits access of coactivators to AF-2, and 
possibly to other regions (Walesky and Apte, 2015). 
The DBD consists of two zinc fingers, and 12 alpha 
helices that create a hydrophobic pocket for ligand 
binding (Duda et al., 2004) (Figure 2). 
HNF4A binds DNA regulatory elements as a 
homodimer. E domain (Ligand Binding Domain-
LBD) appears to be critical for homodimerization 
and to play a role in preventing heterodimerization 
with other NRs such as RXR or RAR (Bogan et al., 
2000). HNF4A binds DNA response elements 
consisting of direct repeats. It can also bind several 
different co-activators (such as GRIP1, NCOA1, 
NCOA2, NCOA3, (SRC1, 2 and 3), CREBBP 
(CBP/P300), PPARGC1A (PGC1)) (MartÍnez-
Jiménez et al., 2006). 
Expression 
Multiple HNF4A isoforms exist in humans and are 
suggested to have different physiological roles in 
development and transcriptional regulation of target 
genes (Figure 1). HNF4A1 and 2 isoforms from the 
P1 promoter are expressed in the liver (hepatocytes), 
kidneys, small intestine and colon. HNF4A3 and 4 
are expressed in human liver. P2 promoter-driven 
HNF4A7 and 8 are expressed in the fetal liver and 
adult pancreas (β-cells) and to a lesser extent in the 
adult liver (bile ducts), small intestine, colon and 
stomach. HNF4A isoforms from both the P1 and P2 
promoter were also reported to be expressed in the 
epididymis (Tanaka et al., 2006). However, not 
much is known about the developmental and 
physiological relevance of the HNF4A isoforms 
(Boyd et al., 2009). 
In addition to several different isoforms produced 
from the HNF4A gene by different promoter usage 
and alternative splicing, the 3'UTR of the gene was 
also reported to control HNF4A expression (Wirsing 
et al., 2011). 
Localisation 
Localized primarily in the nucleus. 
Function 
HNF4A can exist in an unliganded form, or may bind 
to linoleic acid (LA), an essential fatty acid (Yuan et 
al., 2009). Although it is not yet clear whether ligand 
binding affects the function of HNF4A, the HNF4A 
transcriptional activity is regulated at several 
different levels. Most prominent among the post-
translational modifications of HNF4A is 
phosphorylation which occurs mainly at serine and 
to a lesser extent at threonine residues (Jiang et al., 
1997). Between the kinases, PRKACA (protein 
kinase A, PKA) dependent phosphorylation of 
HNF4A was reported to inhibit recruitment to target 
genes (You et al., 2002). On the other hand, 
activation of MAP kinase pathway was shown to 
down-regulate HNF4A transcription (Reddy et al., 
1999). AMP-activated protein kinase was also 
implicated in the regulation of HNF4A activity by 
inhibiting dimer formation and decreasing protein 
stability (Hong et al., 2003). p38 kinase-mediated 
Ser158 phosphorylation was also shown to increase 
DNA binding and transactivation potential of 
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HNF4A (Guo et al., 2006), and Ser78 
phosphorylation of HNF4A by PRKCB (protein 
kinase C, PKC) was shown to down-regulate 
HNF4A protein level via the proteasome pathway 
(Sun et al., 2007). 
Acetylation was also implicated in the regulation of 
HNF4A function (Soutoglou et al., 2000; Yokoyama 
et al., 2011). Soutoglou et al. showed that CREB-
binding protein (CBP) acetylates HNF4A on lysine 
residues within the nuclear localization sequence, 
and increase nuclear retention and target gene 
activation by HNF4A (Soutoglou et al., 2000). 
Methylation and SUMOylation are the other post-
translational mechanisms that regulate HNF4A 
activity. Methylation of the DNA-binding domain of 
HNF4A by PRMT1 (Protein Arginine 
Methyltransferase 1), whose methylation activity on 
HIST4H4 (histone H4 )strongly correlates with the 
induction of HNF4A target genes in differentiating 
enterocytes, increased transcriptional activity of 
HNF4A (Barrero and Malik, 2006). SUMOylation is 
the other mechanism that regulates HNF4A protein 
stability and potentially DNA binding activity (Zhou 
et al., 2012). 
As a transcription factor, HNF4A was first identified 
to be bound to DNA sites required for the 
transcription of two liver-specific genes: TTR 
(transthyretin) and APO3 (apolipoprotein CIII) 
(Sladek et al., 1990). An increasing number of 
studies implicate a vital role of HNF4A in the 
development of the liver, intestine and pancreas, 
differentiation and homeostasis (Figure 3). 
Liver 
HNF4A has been shown to be required for 
hepatocyte differentiation and development of the 
liver. The expression of HNF4A mRNA in post-
implantation mouse embryos was found in the 
primary endoderm starting at day 4.5. From day 8.5, 
HNF4A mRNA was detected in embryonic tissues in 
the liver diverticulum and the hindgut. At later times, 
HNF4A transcripts were found in the mesonephric 
tubules, pancreas, stomach, intestine, and in the 
metanephric tubules of the developing kidney 
(Duncan et al., 1994). Additionally, conditional 
genetic removal of HNF4A in the liver resulted in 
disorganization of morphological and functional 
differentiation in the hepatic epithelium (Parviz et 
al., 2003). In hepatocyte-specific knock-out model, 
lack of HNF4A expression in the liver caused 
impaired lipid metabolism and gluconeogenesis 
(Hayhurst et al., 2001), indicating that HNF4A 
controls genes involved in hepatic lipid and glucose 
metabolism, hereby influencing the hepatocyte 
metabolome (Parviz et al., 2003). On the other hand, 
homozygous loss of HNF4A gene resulted in 
embryonic lethality (Chen et al., 1994.). 
HNF4A was also found to be related to epithelial cell 
adhesion and junction formation in the fetal liver 
(Battle et al., 2006). Re-expression of HNF4A was 
shown to induce cells to reform junctions and 
express hepatocyte marker genes in a 
dedifferentiated hepatoma cell line (Späth and 
Weiss, 1997; Späth and Weiss, 1998). More 
recently, HNF4A was implicated in the 
differentiation of hepatic stellate cells into 
hepatocyte-like cells (Liu et al., 2015). Furthermore, 
in non-hepatic cells, ectopic over expression of 
HNF4A in fibroblasts induced mesenchymal to 
epithelial transition (EMT), indicating that HNF4A 
is a dominant regulator of the morphogenetic 
parameters that form the epithelial phenotype 
(Parviz et al., 2003.). 
More recently, Yang et al. showed that during EMT, 
there is a negative feedback loop between Wnt-β-
catenin signaling and HNF4A, both in vivo and in 
vitro. Restoring HNF4A expression was suggested 
as a method to inhibit invasion in hepatocellular 
carcinoma by preventing EMT (Yang et al., 2013). 
Intestine 
HNF4A plays essential roles in the intestine, 
particularly in epithelial cell function, differentiation 
and normal colon physiology (Chellappa et al., 
2012). 
To directly address the role of HNF4A in 
development of the colon, an epithelial-specific 
knockout model of HNF4A was created in mice by 
using the Cre-loxP system. Examination of the 
embryos revealed that HNF4A ablation disrupts 
development of normal crypt topology in fetal 
colons, and reduced goblet cell maturation (Garrison 
et al., 2006). In adult small intestine, HNF4A was 
shown to play a critical role in the homeostasis of 
intestinal epithelium, in the epithelial cell 
architecture, and in the barrier function of the 
intestine. Loss of intestinal HNF4A affected the 
Wnt/β-catenin signaling pathway, and destabilized 
adherens and tight junctions (Cattin et al., 2009). 
Recently, Vuong et al. suggested that HNF4A 
isoforms play distinct roles in colon cancer, which 
could be caused by differential interactions with the 
Wnt/β-catenin/TCF4 and AP-1 pathways (Vuong et 
al., 2015). 
Importance of HNF4A in the formation of tight 
epithelial barrier to exert a selective barrier function 
in relation to apical-to-basal transport was also 
shown in a coculture system (Lussier et al., 2008). 
Besides nutrient metabolism (Black, 2007) and 
protection against pathogens (Laukoetter et al., 
2006), another function of the epithelial barrier is the 
control of appropriate ion selectivity. Loss of this 
function can lead to deregulation of colonic 
inflammatory homeostasis and inflammatory bowel 
disease (IBD) (Darsigny et al., 2009). 
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Differentiation program in the colon  
Figure 3 HNF4A can regulate different cell functions.  HNF4A is an important regulator with a strong impact on endodermal 
development, organ differentiation and metabolism (Boyd et al., 2009). 
 
HNF4A appears to play a protective role against 
IBD, an important risk factor for colorectal cancer. 
In patients with IBD, HNF4A expression was 
significantly decreased. Accordingly, intestine 
specific HNF4A-null mice exhibited increased 
susceptibility to dextran sulfate sodium (DSS) 
induced IBD with increased intestinal permeability, 
suggesting that HNF4A was required to protect the 
epithelium during experimental colitis (Ahn et al., 
2008). 
HNF4A was also addressed as a crucial transcription 
factor in the differentiation of intestinal cells.  
Intestine specific knockout of HNF4A in the adult 
mouse enhanced proliferation in crypts, and 
increased number of mucus secreting cells (Cattin et 
al., 2009).  
HNF4A was also shown to be involved in the 
regulation of genes involved in the enterocyte 
differentiation and in lipid metabolism (Béaslas et 
al., 2008; Stegmann et al. 2006; Cattin et al., 2009).  
To address the role of HNF4A in differentiation 
dependent transcription in human colonic epithelial 
cells, Boyd et al. performed a genome-wide 
identification of promoters that are occupied by 
HNF4A in vivo.  
The analysis revealed that HNF4A was mostly 
associated with the promoter regions involved in 
transport and metabolism.  
HNF4A was found to regulate differentiation 
dependent transcription by regulating the expression 
of HNF1A and CDX2, transcription factors 
necessary for the expression of many intestinal genes 
important in the development and differentiation 
program in the colon (Boyd et al., 2009). 
 
Pancreas 
HNF4A activity is essential for β-cell function 
through the regulation of several genes, including 
those involved in metabolism-secretion coupling, 
such as glucose transporter-2, L-pyruvate kinase, 
aldolase B, 2-oxoglutarate dehydrogenase E1 
subunit, mitochondrial uncoupling protein-2 (Wang 
et al., 2000) and the potassium channel subunit 
Kir6.2 (Gupta et al., 2005), as well as the INS 
(insulin gene) (Wang et al, 2000; Bartoov-Shifman 
et al., 2002). In pancreatic β-cells, HNF4A maintains 
glucose homeostasis (Marcil et al., 2015; Wang et 
al., 2000). Gene expression analysis in type 2 
diabetes (T2D) patients compared to normal 
glucose-tolerant controls revealed that HNF4A 
mRNA level decreased in pancreatic β-cells of T2D 
patients (Gunton et al., 2005). Moreover, HNF4A 
mutations were implicated in Mature-Onset Diabetes 
of the Young 1 (MODYI), a dominantly inherited 
atypical subgroup of T2D characterized by 
decreased glucose stimulated insulin secretion in 
pancreatic β-cells (Yamagata et al., 1996). More 
recently, it was suggested lack of HNF4A function 
disrupts Ca2+ signaling and insulin release in β-cells 
of patients with MODYI through altered 
endoplasmic reticulum (ER) Ca2+ homeostasis 
(Moore et al., 2016). 
Homology 
HNF4A is highly conserved across species, with 
100% amino acid conservation in the DNA binding 
domain of all mammalian HNF4A. HNF4A has been 
found in every animal organism examined thus far, 
including sponge and coral, and has been postulated 
to be the ancestor of the entire NR family (Bolotin et 
al., 2011) (Table 1 and Figure 4). 
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Table 1 Pairwise alignment of HNF4A gene and protein sequences  (in distance from human). HNF4A is highly conserved 
evolutionarily. 
 
 
Figure 4 HNF4A proteins and their conserved domain architectures. HNF4A is a member of the nuclear receptor (NR) 
family of transcription factors that use conserved DNA binding domains (DBDs) and ligand binding domains (LBDs). 
 
Mutations 
HNF4A is at the center of a complex transcriptional 
regulatory network and is implicated to several 
human diseases including diabetes (Mohlke and 
Boehnke, 2005), MODY1 (Ryffel, 2001), 
hemophilia (Reijnen et al., 1992) and hepatitis B 
viral infections (He et al., 2012).  The HNF4A locus 
has been associated with high-density lipoprotein 
cholesterol (HDL-C) (Teslovich et al., 2010) and 
metabolic dyslipidemia (Suviolahti et al., 2006).  
Finally, since it regulates several Phase I/II and other 
genes in the liver, HNF4A is suggested to play a role 
in drug metabolism (Hwang-Verslues and Sladek, 
2010). In addition, polymorphisms (Hwang-
Verslues and Sladek, 2010; Ruchat et al., 2009; 
Marcil et al., 2015) and mutations (Ryffel, 2001) in 
the human HNF4A gene are associated with altered 
expression and transcriptional activity. 
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Germinal 
Diabetes mellitus, noninsulin-dependent 
(NIDDM):  
In early disease onset, three mutations affecting 
HNF4A function were identified (D126Y; D126H; 
R154Q) (Aguilar-Salinas et al., 2001). In late onset, 
missense mutations were identified in the LBD 
(R323H) (Price et al., 2000) and the F domain 
(V393I); the latter resulted in a reduced 
transactivational activity (Hani et. al., 1998). V255M 
mutation has also been shown to reduce 
transactivation, albeit modestly (Mohlke and 
Boehnke, 2005).  
Thirteen single nucleotide polymorphisms (SNPs) in 
the P2 promoter, three of which were identified in 
Pima Indians, have also been associated with T2D 
(Muller et al. 2005). A 7 bp deletion in the Sp1 site 
of the P1 promoter was identified in type II diabetic 
nephropathic Caucasian patients (Price et al., 2000). 
Factor VII deficiency:  
Homozygous mutation for a T to G transversion at 
nucleotide -61 position in the factor VII promoter 
was shown to disrupt HNF4A binding and result in a 
significant reduction in factor VII promoter activity 
(Arbini et al., 1997). 
Maturity-onset diabetes of the young, type 1 
(MODY1):  
Mutations in the HNF4A coding region and 
promoter were shown to be directly implicated in 
MODY1 in several different human populations 
(Ryffel, 2001).  
Two deletion mutations (F75fsdelT and 
K99fsdelAA) generate truncated proteins lacking 
part of the zinc finger domain essential for DNA 
binding. An in-frame insertion mutation, V328ins, 
located in the LBD, was suggested to alter the highly 
conserved structural organization of the protein. 
R154X and Q268X nonsense mutants retain the 
DNA binding domain but lack a substantial portion 
of the potential ligand binding part (Ryffel, 2001). 
R127W and E276Q missense mutations were 
reported to result in a significant loss of HNF4A 
activity (Lausen et al., 2000). The HNF4A mutations 
G115S (Oxombre et al., 2004.); R127W (Furuta et 
al., 1997); R244Q (Hara et al., 2002.); R324H (Price 
et al., 2000.); IVS5-2delA (Barrio et al., 2002) have 
also been associated with MODY1. Of note, -146T-
>C in the P2 promoter region was reported to be 
associated with MODY1 by affecting PDX1 (IPF-1) 
binding to DNA (Thomas et al., 2001).  
Familial Hyperinsulinism due to HNF4A 
deficiency (FHI-HNF4A):  
Familial hyperinsulinism due to HNF4A deficiency 
is a form of diazoxide-sensitive diffuse 
hyperinsulinism (DHI), characterized by 
macrosomia, transient or persistent 
hyperinsulinemic hypoglycemia (HH), 
responsiveness to the diazoxide and a propensity to 
develop MODY1 (Glaser, 2013). The transmission 
is autosomal dominant with variable penetrance 
(Pearson et al., 2007; Kapoor et al., 2008). 
Implicated in 
Gastric adenocarcinoma 
HNF4A expression was seen in primary gastric 
adenocarcinomas and in metastases of gastric 
carcinoma to the breast, but was absent in primary 
breast carcinomas, and in metastases of breast 
carcinomas to the stomach (van der Post t al., 2014). 
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